• Profile
Close

Baloxavir marboxil for uncomplicated influenza in adults and adolescents

New England Journal of Medicine Sep 11, 2018

Hayden FG, et al. – Researchers assessed the efficacy of baloxavir marboxil, a selective inhibitor of influenza cap-dependent endonuclease, for the treatment of uncomplicated influenza in adults and adolescents. Findings suggested that single-dose baloxavir marboxil was safe and superior to placebo in alleviating influenza symptoms, and was superior to oseltamivir and placebo in reducing the viral load 1 day following initiation of the trial regimen in patients with uncomplicated influenza. Evidence for the development of decreased susceptibility to baloxavir marboxil following treatment was also reported.

Methods

  • Two randomized, double-blind, controlled trials were conducted, enrolling otherwise healthy outpatients with acute uncomplicated influenza.
  • During the 2016–2017 season, following a dose-ranging (10 mg to 40 mg), placebo-controlled trial, a placebo- and oseltamivir-controlled trial of single, weight-based doses of baloxavir marboxil (40 mg or 80 mg) in patients aged 12 to 64 years was conducted.
  • Oseltamivir 75 mg was administered twice daily for 5 days.
  • The time to alleviation of influenza symptoms in the intention-to-treat infected population was the primary efficacy end point.

Results

  • In the phase 2 trial, the median time to alleviation of influenza symptoms was 23.4 to 28.2 hours shorter in the baloxavir marboxil groups vs the placebo group (P < 0.05).
  • In the phase 3 trial, 1,064 patients were included in the intention-to-treat infected population; influenza A(H3N2) infection was observed in 84.8% to 88.1% of patients in each group.
  • With baloxavir marboxil treatment, the median time to alleviation of symptoms was 53.7 hours (95% confidence interval [CI]: 49.5–58.5) vs 80.2 hours (95% CI: 72.6–87.1) with placebo (P < 0.001).
  • With baloxavir marboxil and oseltamivir, time to alleviation of symptoms was similar.
  • Baloxavir marboxil was associated with greater reductions in viral load 1 day following initiation of the regimen vs placebo or oseltamivir.
  • Of those treated with baloxavir marboxil, adverse events (AEs) were observed in 20.7% of recipients; in the placebo and oseltamivir groups, AEs were reported in 24.6% and 24.8% of recipients, respectively.
  • Of those treated with baloxavir marboxil in the phase 2 and 3 trials, emergence of polymerase acidic protein variants with I38T/M/F substitutions conferring reduced susceptibility to baloxavir marboxil occurred in 2.2% and 9.7% of recipients, respectively.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay